These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38511270)

  • 1. Longitudinal data of serum creatine kinase levels and motor, pulmonary, and cardiac functions in 337 patients with Duchenne muscular dystrophy.
    Awano H; Nambu Y; Itoh C; Kida A; Yamamoto T; Lee T; Takeshima Y; Nozu K; Matsuo M
    Muscle Nerve; 2024 May; 69(5):604-612. PubMed ID: 38511270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes of serum creatine kinase levels in children with Duchenne muscular dystrophy].
    Sun SC; Peng YS; He JB
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):35-7. PubMed ID: 18289468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging.
    Batra A; Barnard AM; Lott DJ; Willcocks RJ; Forbes SC; Chakraborty S; Daniels MJ; Arbogast J; Triplett W; Henricson EK; Dayan JG; Schmalfuss C; Sweeney L; Byrne BJ; McDonald CM; Vandenborne K; Walter GA
    BMC Cardiovasc Disord; 2022 Jun; 22(1):260. PubMed ID: 35681116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CM; Franco JV
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013720. PubMed ID: 34850383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The natural history of the patients with Duchenne muscular dystrophy in Taiwan: A medical center experience.
    Liang WC; Wang CH; Chou PC; Chen WZ; Jong YJ
    Pediatr Neonatol; 2018 Apr; 59(2):176-183. PubMed ID: 28903883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characteristics and changes of cardiac injury with age in children of Duchenne muscular dystrophy: a prospective cohort study].
    Hu M; Xu T; Xu K; Guo YK; Yu L; Xu HY; Cai XT; Fu H
    Zhonghua Er Ke Za Zhi; 2024 Mar; 62(3):223-230. PubMed ID: 38378283
    [No Abstract]   [Full Text] [Related]  

  • 7. A longitudinal study of creatine kinase and creatinine levels in Duchenne muscular dystrophy.
    Zygmunt AM; Wong BL; Horn PS; Lambert J; Bange JE; Rybalsky I; Chouteau W; Tian C
    Muscle Nerve; 2023 Feb; 67(2):138-145. PubMed ID: 36444146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of genotype on outcomes in individuals with Duchenne muscular dystrophy: A systematic review.
    Szabo SM; Gooch KL; Mickle AT; Salhany RM; Connolly AM
    Muscle Nerve; 2022 Mar; 65(3):266-277. PubMed ID: 34878187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls.
    Iff J; Done N; Tuttle E; Zhong Y; Wei F; Darras BT; McDonald CM; Mercuri E; Muntoni F
    Muscle Nerve; 2024 Jul; 70(1):60-70. PubMed ID: 38482981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy.
    Tandon A; Villa CR; Hor KN; Jefferies JL; Gao Z; Towbin JA; Wong BL; Mazur W; Fleck RJ; Sticka JJ; Benson DW; Taylor MD
    J Am Heart Assoc; 2015 Mar; 4(4):. PubMed ID: 25814625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac involvement in Fukuyama muscular dystrophy is less severe than in Duchenne muscular dystrophy.
    Yamamoto T; Taniguchi-Ikeda M; Awano H; Matsumoto M; Lee T; Harada R; Imanishi T; Hayashi N; Sakai Y; Morioka I; Takeshima Y; Iijima K; Saegusa J; Toda T
    Brain Dev; 2017 Nov; 39(10):861-868. PubMed ID: 28578814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic deletion of
    Stirm M; Shashikadze B; Blutke A; Kemter E; Lange A; Stöckl JB; Jaudas F; Laane L; Kurome M; Keßler B; Zakhartchenko V; Bähr A; Klymiuk N; Nagashima H; Walter MC; Wurst W; Kupatt C; Fröhlich T; Wolf E
    Proc Natl Acad Sci U S A; 2023 Jul; 120(29):e2301250120. PubMed ID: 37428903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.
    Wein N; Alfano L; Flanigan KM
    Pediatr Clin North Am; 2015 Jun; 62(3):723-42. PubMed ID: 26022172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic modifiers of respiratory function in Duchenne muscular dystrophy.
    Bello L; D'Angelo G; Villa M; Fusto A; Vianello S; Merlo B; Sabbatini D; Barp A; Gandossini S; Magri F; Comi GP; Pedemonte M; Tacchetti P; Lanzillotta V; Trucco F; D'Amico A; Bertini E; Astrea G; Politano L; Masson R; Baranello G; Albamonte E; De Mattia E; Rao F; Sansone VA; Previtali S; Messina S; Vita GL; Berardinelli A; Mongini T; Pini A; Pane M; Mercuri E; Vianello A; Bruno C; Hoffman EP; Morgenroth L; Gordish-Dressman H; McDonald CM; ; Pegoraro E
    Ann Clin Transl Neurol; 2020 May; 7(5):786-798. PubMed ID: 32343055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests.
    Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP
    Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left ventricular dysfunction in Duchenne muscular dystrophy.
    James KA; Gralla J; Ridall LA; Do TN; Czaja AS; Mourani PM; Ciafaloni E; Cunniff C; Donnelly J; Oleszek J; Pandya S; Price E; Yang ML; Auerbach SR
    Cardiol Young; 2020 Feb; 30(2):171-176. PubMed ID: 31964455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.
    Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G
    Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy.
    Tsabari R; Simchovitz E; Lavi E; Eliav O; Avrahami R; Ben-Sasson S; Dor T
    Neuromuscul Disord; 2021 Sep; 31(9):803-813. PubMed ID: 34304968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.